Cargando…

Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma

BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions (DLI) may induce a graft-versus-tumor effect in pediatric sarcoma patients. Here, we describe general feasibility, toxicity and efficacy of DLI after allo-SCT. RESULTS: 4 of 8 patients responded. ES#4 had stab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schober, Sebastian J., von Luettichau, Irene, Wawer, Angela, Steinhauser, Maximilian, Salat, Christoph, Schwinger, Wolfgang, Ussowicz, Marek, Antunovic, Petar, Castagna, Luca, Kolb, Hans-Jochem, Burdach, Stefan E.G., Thiel, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978262/ https://www.ncbi.nlm.nih.gov/pubmed/29854312 http://dx.doi.org/10.18632/oncotarget.25228

Ejemplares similares

Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow
por: Thiel, Uwe, et al.
Publicado: (2016)

No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease
por: Thiel, U., et al.
Publicado: (2021)

Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease
por: Thiel, U., et al.
Publicado: (2021)

Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing’s Sarcoma, Enhancing T Cell Cytotoxicity
por: Biele, Emilie, et al.
Publicado: (2021)

The Vigor of Defense Against Non-Self: Potential Superiority of Allorestricted T Cells in Immunotherapy of Cancer?
por: Burdach, Stefan, et al.
Publicado: (2013)

No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy
por: Schober, Sebastian Johannes, et al.
Publicado: (2022)

T Cells Directed against the Metastatic Driver Chondromodulin-1 in Ewing Sarcoma: Comparative Engineering with CRISPR/Cas9 vs. Retroviral Gene Transfer for Adoptive Transfer
por: Xue, Busheng, et al.
Publicado: (2022)

Sclerosing Epithelioid Fibrosarcoma of the Bone: A Case Report of High Resistance to Chemotherapy and a Survey of the Literature
por: Grunewald, Thomas G. P., et al.
Publicado: (2010)

Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function
por: Gassmann, Hendrik, et al.
Publicado: (2021)

The Phenotype and Treatment of WIP Deficiency: Literature Synopsis and Review of a Patient With Pre-transplant Serial Donor Lymphocyte Infusions to Eliminate CMV
por: Schwinger, Wolfgang, et al.
Publicado: (2018)

MHC Class I-Restricted TCR-Transgenic CD4(+) T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo
por: Schober, Sebastian J., et al.
Publicado: (2020)

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity
por: Herzog, J., et al.
Publicado: (2016)

Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases
por: Wernicke, Caroline M, et al.
Publicado: (2011)

Understanding anti-leukemia responses to donor lymphocyte infusion
por: Bachireddy, Pavan, et al.
Publicado: (2014)

Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo
por: Kirschner, Andreas, et al.
Publicado: (2017)

Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia
por: Rujkijyanont, P, et al.
Publicado: (2013)

Precision medicine in pediatric oncology
por: Burdach, Stefan E. G., et al.
Publicado: (2018)

Correction to: Precision medicine in pediatric oncology
por: Burdach, Stefan E. G., et al.
Publicado: (2022)

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia
por: Reagan, J L, et al.
Publicado: (2015)

Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma
por: Prexler, Carolin, et al.
Publicado: (2022)

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy
por: Weidenbusch, Bushra, et al.
Publicado: (2018)

Donor Cell Myeloid Sarcoma
por: Walshauser, Mark A., et al.
Publicado: (2014)

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
por: Buhmann, Raymund, et al.
Publicado: (2013)

Graft‐versus‐mastocytosis effect after donor lymphocyte infusion: Proof of principle
por: Hägglund, Hans, et al.
Publicado: (2020)

Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion
por: McCurdy, Shannon R.
Publicado: (2022)

Intravenous Lignocaine Infusion for Intractable Pain in Ewing's Sarcoma
por: Page, Nivedita
Publicado: (2018)

Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma
por: Evdokimova, Valentina, et al.
Publicado: (2022)

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023)

Low incidence and morbidity of Epstein‐Barr virus reactivation following donor lymphocyte infusions
por: Martinovic, Danilo, et al.
Publicado: (2023)

Pretransplant Infusion of Donor B Cells Enhances Donor-Specific Skin Allograft Survival
por: Gao, Julia, et al.
Publicado: (2013)

Granulocytic sarcoma as isolated extramedullary relapse after donor lymphocyte infusion in a patient with CML who relapsed after allogeneic bone marrow transplantation: a case report.
por: Lee, J. J., et al.
Publicado: (1998)

Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by Donor Lymphocyte Infusion in Established Mixed Allogeneic Hematopoietic Chimeras
por: Wang, Hui, et al.
Publicado: (2012)

Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation
por: Przystupski, Dawid, et al.
Publicado: (2022)

Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation
por: Reinwald, Mark, et al.
Publicado: (2014)

Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner
por: Jahnke, Simona, et al.
Publicado: (2019)

Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells
por: Kwon, Yong-Rim, et al.
Publicado: (2020)

Comparison of Two Strategies for Prophylactic Donor Lymphocyte Infusion in Patients With Refractory/Relapsed Acute Leukemia
por: Su, Qiongqiong, et al.
Publicado: (2021)

Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome
por: Park, Silvia, et al.
Publicado: (2021)

Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment
por: Thiel, U, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4cke9ovda7l9ukaitamghtlloh